雷珠单抗与阿柏西普玻璃体腔注射治疗渗出性年龄相关性黄斑变性的疗效观察

目的:探究雷珠单抗与阿柏西普玻璃体腔注射治疗渗出性年龄相关性黄斑变性的临床疗效与安全性。方法:选取2015年5月～2018年5月我院收治的渗出性年龄相关性黄斑变性患者98例(98眼),采用随机数字表法将患者分为两组,A组玻璃体腔内缓慢注射0.05 m L(0.5 mg)雷珠单抗注射液,B组玻璃体腔内缓慢注射0.05 m L(2 mg)阿柏西普注射液。比较两组患者的视力改善情况、眼动脉血流动力学、黄斑中心凹视网膜厚度及不良反应的发生情况。结果:治疗前两组患者的视力比较无统计学差异(P0.05),治疗后,B组视力显著高于A组(P0.05);。两组患者治疗前后眼动脉血流动力学相关指标比较均无统计学差异(P0.05)。;两组患者治疗后的黄斑中心凹视网膜厚度均显著降低,且治疗3个月B组治疗3个月显著低于A组(P0.05);B组患者注射药物后结膜下大出血发生率显著低于A组(P0.05)。结论:阿柏西普可显著改善渗出性年龄相关性黄斑变性患者的视力,且安全性高,可能与其可显著改善患者的黄斑中心凹视网膜厚度有关,且不良反应发生率低,安全性好。

Observation on the Therapeutic Effect of Lucentis and Aflibercept Intravitreal Injection in the Treatment of Exudative Age-related Macular Degeneration

ABSTRACT Objective: To investigate the efficacy and safety of intravitreal injection of lucentis and aflibercept in the treatment of exudative age-related macular degeneration. Methods: 98 cases of patients (98 eyes) with exudative age-related macular degeneration admitted to our hospital from May 2015 to May 2018 were enrolled and divided into two groups by the random number table. Group A was slowly injected in the vitreous cavity with 0.05 mL (0.5 mg) of ranibizumab injection, 0.05 mL (2 mg) of aboxicept was slowly injected into the vitreous cavity of group B. The vision improvement, ocular arterial hemodynamics, macular foveal retinal thickness and adverse reactions were compared between the two groups. Results: There was no significant difference in vision between the two groups before treatment (P>0.05). After treatment, the vision of group B was significantly higher than that of group A (P<0.05). There was no statistical difference in the ocular arterial hemodynamics between the two groups before and after treatment(P>0.05). The thickness of foveal retinal fove after treatment was significantly lower in both groups, and it was significantly lower in the group B than that in the group A (P<0.05). The incidence of subconjunctival hemorrhage was significantly lower in the group B than that in the group A (P<0.05). Conclusion: Aflibercept can significantly improve the vision of patients with exudative age-related macular degeneration with high safety, which may be related to the significantly improvedment of macular fovea retinal thickness, and the incidence of adverse reactions is low and the safety is good.